Advancing Immunotherapy in Osteosarcoma


October 15, 2026 to October 17, 2026

Osteosarcoma is the most common primary malignant bone tumor, predominantly affecting children, adolescents, and young adults. While the introduction of multimodal therapy combining surgical resection with cytotoxic chemotherapy in the 1970s significantly improved survival for localized disease, therapeutic progress has largely plateaued over the past several decades. Outcomes for patients with recurrent or metastatic osteosarcoma remain particularly poor, with survival rates of only 25–30%. Efforts to apply existing immune checkpoint blockades have yielded limited results due to biological barriers including a low mutational burden, an immunosuppressive tumor microenvironment, and reduced MHC class I expression—underscoring the urgent need for next-generation immunotherapeutic strategies.

To accelerate progress in this space, The Mark Foundation for Cancer Research and The Osteosarcoma Institute (OSI) jointly convened a workshop in Dallas, TX, in October 2026. The workshop, titled “Advancing Immunotherapy in Osteosarcoma,” was organized by a team of leading experts: Catherine Bollard, MBChB, MD, of Children’s National Hospital and The George Washington University, Richard Gorlick, MD, of MD Anderson Cancer Center, and Patrick Hwu, MD, of Moffitt Cancer Center.

The workshop brought together 34 surgeons, clinicians, veterinarians, and researchers from around the world—uniting dedicated osteosarcoma specialists with leaders from outside the field to spark new interdisciplinary connections and robust scientific discussions. Sessions focused on overcoming the immunosuppressive tumor microenvironment; harnessing host-tumor interactions through novel cellular and vaccine-based strategies; advancing next-generation CAR T-cell engineering for solid tumors; profiling the osteosarcoma surfaceome to identify tumor-selective targets; and leveraging molecular characterization to guide precision immunotherapy.

Following the workshop, The Mark Foundation for Cancer Research and The Osteosarcoma Institute are launching a dedicated request for proposals (RFP) to fund collaborative, high-impact projects emerging from the meeting.

Event Images

Click on any image to see more!

Back to all events